Lazard Capital upgrades St. Jude Medical (STJ +3.2%) to Buy, questioning concerns about a Durata...

Lazard Capital upgrades St. Jude Medical (STJ +3.2%) to Buy, questioning concerns about a Durata defibrillator cable. A report turned up in an FDA database and was said to be due to a fraying issue, prompting fears that problems with STJ's earlier Riata product may not be isolated. But anyone can file to that database, Lazard says, and the cable wasn't returned to STJ for analysis.

From other sites
Comments (3)
  • johnsnare
    , contributor
    Comments (19) | Send Message
    Up,up, and away.
    18 Jun 2012, 02:11 PM Reply Like
  • Danorama
    , contributor
    Comments (24) | Send Message
    Some have indicated that Lorcaserin provides little benefit to patients. Consider this; it has been largely over looked that Lorcaserin provided a 10% or greater weight loss for twenty-five percent of the subjects in the latest trial.


    Lorcaserin has other advantages over its competor, Qnexa. Lorcaserin is a "novel" drug, meaning that this drug is a completely new drug unlike Qnexa which is a combination of two existing drugs. It is probable that insurance companies will cover the cost of lorcaserin and nearly certain that insurance companies will not cover Qnexa. It is quite possible that the FDA will decide to approve only a "novel" drug, Lorcaserin.


    In addition, the drugs contained in Qnexa are proven to cause birth defects in new borns of women who take Qnexa, it is highly unlikely that doctors will prescribe Qnexa for any female capable of having children.


    Doctors will prefer Lorcaserin over Qnexa and so will patients.
    18 Jun 2012, 06:48 PM Reply Like
  • mozick3
    , contributor
    Comments (19) | Send Message
    Lorcaserin by itself will be relatively ineffective for significant weight-loss. However since most Bariatric physicians will be combining it with phentermine the end result should very nearly equal that of the infamous phen/fen combination. Lorcaserin is very much like the original pondimin however without the rare significant adverse effects of primary pulmonary hypertension and valvulopathy.
    Qnexa will be only modestly effective at best. Using the components of this drug ie phentermine and topiramate as 2 separate drugs in the same patients will be much more effective due to significant dosage adjustments allowed. The maximum dosage of phentermine in the Qnexa combination is 15 mg, whereas using 30 mg of phentermine twice /day is fairly common practice in bBariatric medicine. (400 % higher)
    20 Jun 2012, 12:00 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs